글로벌 콜로보마, 심장 결함, 협착증, 성장 지연, 생식기 이상 및 귀 이상(CHARGE) 증후군 치료 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 규모

CHARGE 증후군은 10,000명의 산아 중 0.1-1.2명에게 영향을 미치는 흔하지 않은 질환입니다. 남녀 모두에게 동일하게 영향을 미치며 모든 민족과 대륙의 사람들에게서 관찰되었습니다. CHARGE는 의학 문헌에 기록된 것보다 훨씬 더 많은 경우에 발생합니다. 많은 경우 치료되지 않거나 잘못 진단되며, 특히 문제가 적은 어린이의 경우 그렇습니다. CHARGE는 한 명의 자녀가 있는 부모의 경우 약 2-3%로 적당한 재발 위험이 있습니다. CHARGE가 있는 성인의 경우 다시 자녀를 낳을 확률은 50%에 달합니다.

Data Bridge Market Research는 콜로보마, 심장 결함, 코막 폐쇄, 성장 지연, 생식기 이상 및 귀 이상(CHARGE) 증후군 치료 시장이 2021년에 4억 7,780만 달러 규모였으며 2029년까지 6억 7,430만 달러에 도달할 것으로 예상되며 2022년에서 2029년까지의 예측 기간 동안 4.40%의 CAGR을 기록할 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자 및 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

보고 범위 및 시장 세분화

시장 정의

CHARGE 증후군은 자녀의 성장, 협응, 행동, 발달 및 지능을 손상시키는 드문 유전적 질환입니다. 또한 외관과 내부 장기에도 영향을 미칩니다. 후두 폐쇄, 구순열, 심장 기형을 포함한 여러 구조적 문제에 대한 수술적 교정이 가능합니다. 수유 곤란, 언어 장애와 같은 다른 증상은 수년간의 치료와 다른 개입이 필요할 수 있습니다. 기관 절개술이 필요했을 CHARGE 증후군이 있는 인공호흡기 의존 신생아의 경우 보툴리눔 독소 A(보톡스)를 사용하여 과도한 타액 분비를 조절합니다. 영향을 받은 개인과 그 가족은 유전 상담을 통해 혜택을 볼 수 있습니다 . 증상에 따른 치료와 지지적 치료가 유일한 다른 옵션입니다.

콜로보마, 심장 결함, 코아나에 폐쇄증, 성장 지연, 생식기 이상 및 귀 이상(CHARGE) 증후군 치료 시장 역학

운전자

• CHARGE 증후군의 유병률 증가

CHARGE 증후군의 유병률이 증가함에 따라 시장 성장률이 높아질 것으로 추정됩니다. CHARGE 증후군은 산발적(97%)이거나 상염색체 우성 유전 패턴을 보입니다. 생식선 모자이크증은 1-2%의 사람들에게 발생합니다. CHARGE 증후군은 어린이마다 다른 다양한 신체적, 정신적 건강 문제로 나타나는 복잡한 장애입니다. CHARGE 증후군이 있는 어린이는 모두 청각, 미각, 시각, 후각, 촉각 감각에 영향을 받습니다. CHARGE 증후군은 선천성 청각 장애와 실명의 가장 흔한 원인 중 하나입니다.

• 의료 인프라에 대한 투자 증가

Another significant factor influencing the growth rate of coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, surging number of government initiatives to spread awareness and increasing level of disposable income will result in the expansion of coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market. Along with this, changing lifestyle of people and growing awareness about the early genetic diagnosis will enhance the growth rate of the market.

Opportunities

• Increase in the number of research and development activities    

The coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market growth.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market. Additionally, a decline in clinical visits due to COVID-19 outbreak and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Global Coloboma, Heart Defects, Atresia Choanae, Growth Retardation, Genital Abnormalities, and Ear Abnormalities (CHARGE) Syndrome Treatment Market Scope

The coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market is segmented on the basis of treatment, diagnosis, route of administration, dosage form, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Botulinum toxin A
• Surgery
• Occupational Therapy
• Physical Therapy
• Speech Therapy
• Others

Diagnosis

• Genetic Testing
• Blood Tests
• Imaging Tests
• Chest X-ray
• Cranial ultrasonography
• Computed tomography (CT) scan
• Magnetic resonance imaging (MRI)
• Abdominal ultrasound
• Skeletal survey
• Echocardiography
• Others

Route of Administration

• Intradermal
• Intramuscular
• Others

Dosage Form

• Powder
• Solution

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Coloboma, Heart Defects, Atresia Choanae, Growth Retardation, Genital Abnormalities, and Ear Abnormalities (CHARGE) Syndrome Treatment Market Regional Analysis/Insights

The coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market is analysed and market size insights and trends are provided by country, treatment, diagnosis, route of administration, dosage form, end-users and distribution channel as referenced above.

The countries covered in the coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market because of the well-established healthcare infrastructure and rising awareness among population in this region. Additionally, growing presence of major key players will further propel the market's growth rate in this region.

Asia-Pacific is expected to grow during the forecast period due to increasing penetration of novel drugs and rising healthcare expenditure in this region. Also, growing government initiatives will further cushion the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Coloboma, Heart Defects, Atresia Choanae, Growth Retardation, Genital Abnormalities, and Ear Abnormalities (CHARGE) Syndrome Treatment Market Share Analysis

콜로보마, 심장 결함, 코아나에 폐쇄, 성장 지연, 생식기 이상, 귀 이상(CHARGE) 증후군 치료 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 프로그램 우세 등이 포함됩니다. 위에 제공된 데이터 포인트는 콜로보마, 심장 결함, 코아나에 폐쇄, 성장 지연, 생식기 이상, 귀 이상(CHARGE) 증후군 치료 시장과 관련된 회사의 초점에만 관련됩니다.

콜로보마, 심장 결함, 후두 폐쇄증, 성장 지연, 생식기 이상 및 귀 이상(CHARGE) 증후군 치료 시장에서 활동하는 주요 업체는 다음과 같습니다.

• F. 호프만-라 로슈 유한회사(스위스)
• 마일런 NV(미국)
• Teva Pharmaceutical Industries Ltd. (아일랜드)
• 사노피(프랑스)
• 파이저 주식회사(미국)
• GlaxoSmithKline plc (영국)
• 노바티스 AG(스위스)
• Bayer AG(독일)
• 엘리 릴리 앤드 컴퍼니(미국)
• 머크앤코(미국)
• 알러간(아일랜드)
• 아스트라제네카(영국)
• AbbVie Inc.(미국)
• 존슨앤존슨 프라이빗 리미티드(미국)
• 시플라 주식회사(미국)  
• 애벗(미국)
• 머크 KGaA(독일)
• LEO Pharma A/S(덴마크)
• Bausch Health Companies Inc. (캐나다)
• Sun Pharmaceutical Industries Ltd. (인도)
• Aurobindo Pharma(인도)
• 루팡(인도)
• 히크마 제약(영국)
• Fresenius Kabi AG(독일)
• Amneal Pharmaceuticals LLC. (미국)

SKU-68488